) recently announced that it will be presenting new data on two
promising pipeline candidates, omecamtiv mecarbil and AMG-145, at
the upcoming ESC Congress, organized by the European Society of
Cardiology, in early September.
Omecamtiv mecarbil, which is being developed in collaboration
), is being evaluated for the treatment of heart failure. Results
will be presented from the phase IIb ATOMIC-AHF study (Acute
Treatment with Omecamtiv Mecarbil to Increase Contractility in
Acute Heart Failure), which is evaluating the safety,
tolerability and efficacy of an intravenous formulation of
omecamtiv mecarbil in patients with acute heart failure.
Efficacy and safety data on AMG145, Amgen's cholesterol
management candidate, will be presented from a pooled analysis of
four phase II studies including MENDEL, LAPLACE-TIMI 57, GAUSS
Amgen has been in the news recently following its announcement
regarding its plans to acquire
Onyx Pharmaceuticals, Inc.
). With this acquisition, Amgen will be strengthening its
presence in the oncology market. Onyx Pharma basically focuses on
developing and commercializing treatments for cancer. Marketed
products include Kyprolis (relapsed and refractory multiple
myeloma), Nexavar (liver and kidney cancer) and Stivarga
(metastatic colorectal cancer and metastatic gastrointestinal
stromal tumor). Advanced pipeline candidates include palbociclib
(phase III - ER+, HER2-negative advanced breast cancer) and
oprozomib (phase Ib/II - multiple myeloma).
With key products in Amgen's portfolio slated to lose
exclusivity in the coming years, contributions from Onyx Pharma's
products should help make up for a part of the revenues that will
be lost to generic competition.
Amgen currently carries a Zacks Rank #3 (Hold). At present,
) look well-positioned - Biogen carries a Zacks Rank #1 (Strong
AMGEN INC (AMGN): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
CYTOKINETCS INC (CYTK): Free Stock Analysis
ONYX PHARMA INC (ONXX): Free Stock Analysis
To read this article on Zacks.com click here.